Crispr Historical Cash Flow
| CRSP Stock | USD 47.88 1.59 3.43% |
Analysis of Crispr Therapeutics cash flow over time is an excellent tool to project Crispr Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Investments of 294.6 M or Change In Cash of 185.9 M as it is a great indicator of Crispr Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Crispr Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Crispr Therapeutics is a good buy for the upcoming year.
Crispr |
About Crispr Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Crispr balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Crispr's non-liquid assets can be easily converted into cash.
Crispr Therapeutics Cash Flow Chart
Add Fundamental
Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Crispr Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Crispr Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Crispr Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Crispr Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. At this time, Crispr Therapeutics' Change To Inventory is relatively stable compared to the past year. As of 11/25/2024, Change Receivables is likely to grow to about 368.3 K, though Free Cash Flow is likely to grow to (258.7 M).
| 2023 | 2024 (projected) | Stock Based Compensation | 81.0M | 50.7M | Net Borrowings | 31.5M | 29.7M |
Crispr Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Crispr Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Crispr Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 431.0M | 1.0B | 250.9M | 38.6M | 44.4M | 42.2M | |
| Investments | 1.3M | (522.8M) | (953.7M) | (258.7M) | 280.6M | 294.6M | |
| Change In Cash | 489M | 236.7M | (245.5M) | (715.9M) | 177.0M | 185.9M | |
| Stock Based Compensation | 44.1M | 66.0M | 102.4M | 97.9M | 81.0M | 50.7M | |
| Free Cash Flow | 50.0M | (256.7M) | 457.3M | (532.9M) | (272.3M) | (258.7M) | |
| Change In Working Capital | (48.4M) | 33.4M | 26.9M | 19.8M | (193.6M) | (183.9M) | |
| Begin Period Cash Flow | 459.8M | 948.8M | 1.2B | 939.9M | 224.1M | 212.9M | |
| Total Cashflows From Investing Activities | 1.3M | (541.2M) | (1.0B) | (258.7M) | (232.8M) | (244.4M) | |
| Other Cashflows From Financing Activities | 16.0M | 33.9M | 37.7M | 37.6M | 29.9M | 29.0M | |
| Depreciation | 4.7M | 9.2M | 18.0M | 24.2M | 19.8M | 20.8M | |
| Other Non Cash Items | (10.5M) | 1.9M | 14.1M | 12.5M | (14.0M) | (13.3M) | |
| Capital Expenditures | 6.7M | 18.4M | 81.7M | 37.2M | 12.0M | 18.9M | |
| Total Cash From Operating Activities | 56.7M | (238.4M) | 539.0M | (495.7M) | (260.4M) | (247.4M) | |
| Change To Account Receivables | (11K) | (45K) | (161K) | 305K | (200M) | (190M) | |
| Change To Operating Activities | (8.3M) | 6.4M | (9.7M) | 15.4M | 17.7M | 18.6M | |
| Net Income | 66.9M | (348.9M) | 377.7M | (650.2M) | (153.6M) | (161.3M) | |
| Total Cash From Financing Activities | 431.0M | 1.0B | 250.9M | 38.6M | 62.7M | 59.5M | |
| End Period Cash Flow | 948.8M | 1.2B | 939.9M | 224.1M | 401.1M | 535.8M | |
| Change To Netincome | 49.5M | 67.9M | 102.4M | 110.4M | 127.0M | 133.3M | |
| Change To Liabilities | 30.0M | 15.2M | 32.2M | 3.6M | 3.3M | 3.1M | |
| Change To Inventory | (5.0M) | (25.7M) | (37.5M) | 23.3M | 26.8M | 28.2M | |
| Change Receivables | (11K) | (45K) | (161K) | 305K | 350.8K | 368.3K | |
| Cash And Cash Equivalents Changes | 489.0M | 236.6M | (245.5M) | (715.8M) | (644.2M) | (612.0M) | |
| Cash Flows Other Operating | (94.4M) | 18.2M | (5.2M) | 15.9M | 18.3M | 19.2M | |
| Issuance Of Capital Stock | 415.0M | 982.3M | 213.3M | 970K | 32.7M | 31.1M |
Pair Trading with Crispr Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Crispr Stock
| 0.53 | MTEM | Molecular Templates | PairCorr |
| 0.35 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.32 | TCHH | Trustcash Holdings | PairCorr |
| 0.31 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.